Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

1081. Cost effectiveness analysis of a dry powder inhaler (Turbuhaler) versus a pressurised metered dose inhaler in patients with asthma

Cost effectiveness analysis of a dry powder inhaler (Turbuhaler) versus a pressurised metered dose inhaler in patients with asthma Cost effectiveness analysis of a dry powder inhaler (Turbuhaler) versus a pressurised metered dose inhaler in patients with asthma Cost effectiveness analysis of a dry powder inhaler (Turbuhaler) versus a pressurised metered dose inhaler in patients with asthma Liljas B, Stahl E, Pauwels R A Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two different kinds of inhalers: using an aerosol pressurised metered dose inhaler (pMDI) or a dry powder inhaler (Turbuhaler) in patients with asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population

1997 NHS Economic Evaluation Database.

1082. Care of asthma: allergy clinic versus emergency room

and the conclusions drawn. Health technology Allergy clinics and emergency room treatment for asthma. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Asthmatic patients (children) from an inner-city area in the USA. All patients came from low income, working families without medical insurance and were ineligible for Medicaid. Setting Hospital. The study was carried out at the Medical Center of Louisiana in New Orleans, USA. Dates to which data relate (...) Care of asthma: allergy clinic versus emergency room Care of asthma: allergy clinic versus emergency room Care of asthma: allergy clinic versus emergency room Moore C M, Ahmed I, Mouallem R, May W, Ehlayel M, Sorensen R U Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study

1997 NHS Economic Evaluation Database.

1083. Joint consultation for high-risk asthmatic children and their families, with pediatrician and child psychiatrist as co-therapists: model and evaluation

psychiatrist as co-therapists. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised high-risk asthmatic children and their families. 'High-Risk Asthma' was defined according to specific criteria, which were provided in the text. Setting The setting was hospital. The economic study was carried out in Belgium. Dates to which data relate The effectiveness and resource use data were gathered in the period between 1986 and 1990 (...) consultation in the context of childhood asthma. Source of funding None stated Bibliographic details Godding V, Kruth M, Jamart J. Joint consultation for high-risk asthmatic children and their families, with pediatrician and child psychiatrist as co-therapists: model and evaluation. Family Process 1997; 36(3): 265-280 PubMedID Other publications of related interest Aas K. Heterogeneity of bronchial asthma. Allergy 1981;36:3-10. Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Asthma

1997 NHS Economic Evaluation Database.

1084. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. (Abstract)

Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. Inhaled beta-agonists are the most commonly used treatment for asthma, but data suggest that regularly scheduled use of these agents may have deleterious effect on the control of asthma. We compared the effects of regularly scheduled use of inhaled albuterol with those of albuterol used only as needed in patients with mild chronic, stable asthma.In a multicenter, double-blind (...) study, we randomly assigned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or only as needed (129 patients). The patients were followed for 16 weeks.The primary outcome indicator, peak expiratory air flow measured in the morning, did not change significantly during the treatment period in the scheduled (416 liters per minute after the run-in period and 414 liters per minute after the treatment period) or the as-needed (424 liters per minute at both

1996 NEJM Controlled trial quality: uncertain

1085. Ragweed immunotherapy in adult asthma. (Abstract)

Ragweed immunotherapy in adult asthma. Although allergen immunotherapy is effective for allergic rhinitis, its role in treating asthma is unclear.We examined the efficacy of immunotherapy for asthma exacerbated by seasonal ragweed exposure. During an observation phase, adults with asthma who were sensitive to ragweed kept daily diaries and recorded peak expiratory flow rates between July and October. Those who reported seasonal asthma symptoms and medication use as well as decreased peak (...) ) but did not differ in the two groups during the second year (P = 0.7). Asthma-symptom scores were similar in the two groups (P = 0.08 in year 1 and P = 0.3 in year 2). The immunotherapy group had reduced hay-fever symptoms, skin-test sensitivity to ragweed, and sensitivity to bronchial challenges and increased IgG antibodies to ragweed as compared with the placebo group; there was no longer a seasonal increase in IgE antibodies to ragweed allergen in the immunotherapy group after two years

1996 NEJM Controlled trial quality: uncertain

1086. Randomised comparison of guided self management and traditional treatment of asthma over one year. Full Text available with Trip Pro

Randomised comparison of guided self management and traditional treatment of asthma over one year. To compare the efficacy of self management of asthma with traditional treatment.12 month prospective randomised trial.Outpatient clinics in Finland.115 patients with mild to moderately severe asthma.Patient education and adjustment of anti-inflammatory therapy guided by peak flow measurements.Unscheduled admissions to hospital and outpatient visits, days off work, courses of antibiotics (...) and prednisolone, lung function, and quality of life.The mean number of unscheduled visits to ambulatory care facilities (0.5 v 1.0), days off work (2.8 v 4.8), and courses of antibiotics (0.4 v 0.9) and prednisolone (0.4 v 1.0) per patient were lower and the quality of life score (16.6 v 8.4 at 12 months) higher in the self management group than in the traditionally treated group. In both groups admissions for asthma were rare.Self management reduces incidents caused by asthma and improves quality of life.

1996 BMJ Controlled trial quality: uncertain

1087. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. (Abstract)

Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. To study the effect of 3 months of treatment with zileuton, an inhibitor of the enzymatic pathway (5-lipoxygenase) leading to leukotriene formation, on disease control in patients with mild to moderate asthma.Randomized, double-blind, parallel-group study in 401 patients. A 10-day placebo lead-in was followed by a double-blind treatment period (...) of 13 weeks.Asthma study clinics in university hospitals and private practices.Patients with mild to moderate asthma (forced expiratory volume in the first second [FEV1], 40% to 80% of predicted) whose only treatment was inhaled beta-agonists.Treatment with 600 mg or 400 mg of zileuton or placebo (each taken four times daily.)Frequency of asthma exacerbation requiring treatment with corticosteroids, use of inhaled beta-agonists, pulmonary function tests, asthma symptom assessment, and quality

1996 JAMA Controlled trial quality: predicted high

1088. Randomised double-blind placebo-controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin-induced asthma. (Abstract)

Randomised double-blind placebo-controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin-induced asthma. Bronchoconstriction induced by bradykinin is reduced by the release of nitric oxide (NO) in the airways of guinea pigs. Inhaled NO is known to cause bronchodilatation in asthmatic patients. To find out the role of endogenous NO in airway response to bradykinin in asthma, we examined the effect of the NO synthase inhibitor NG-monomethyl-L-arginine (L-NMMA (...) -NMMA (p < 0.01). L-NMMA also caused a decrease in the provocative concentration of methacholine producing a 20% fall in FEV1 from 0.93 mg/mL (range 0.12-2.55 mg/mL) to 0.38 mg/mL (range 0.06-0.92 mg/mL; p < 0.01). In contrast, D-NMMA did not affect airway response to bradykinin or methacholine.The results suggest that bronchoconstriction after bradykinin inhalation is greatly inhibited by the formation of NO in airways of asthmatic patients and that NO could have a bronchoprotective role in asthma.

1996 Lancet Controlled trial quality: uncertain

1089. Organisation of asthma care: what difference does it make. A systematic review of the literature

Organisation of asthma care: what difference does it make. A systematic review of the literature Organisation of asthma care: what difference does it make. A systematic review of the literature Organisation of asthma care: what difference does it make. A systematic review of the literature Eastwood A J, Sheldon T A Authors' objectives To evaluate the effectiveness of different forms of delivery of asthma care. Searching MEDLINE was searched from 1976 to the first quarter of 1995 using (...) the search terms provided in the Appendix. CINAHL, HELMIS, Manchester Primary and Secondary Care Interface, Health Planning and Administration, and DHSS databases were also searched. Additional material was located by examining relevant citations from identified articles, and by contacting members of the National Asthma Guidelines working party. Study selection Study designs of evaluations included in the review The review included all type of studies assessing organisational methods of asthma management

1996 DARE.

1090. [Cost-effectiveness studies of ambulatory educational programs for children with asthma and their families]

for children with asthma and their families] Scholtz W, Haubrock M, Lob-Corzilius T, Gebert N, Wahn U, Szczepanski R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Training programmes for asthmatic children. Type of intervention (...) of stationary in-hospitalisations, number of visits to a doctor due to mild asthmatic attacks, number of visits to a doctor due to strong asthmatic attacks, number of repeated asthma attacks and absence from school. The change in the number of occurrences of each measure was then weighted and valued to receive an effectiveness factor. The sum of all effectiveness factors was the total effectiveness factor, where a higher value stands for higher effectiveness reflecting an improvement in children's quality

1996 NHS Economic Evaluation Database.

1091. Economic analysis of two structured treatment and teaching programs on asthma

", the authors "agree that the key features of an asthma program should be proper treatment and regular supervision of asthmatics." Measure of benefits used in the economic analysis The benefit measures were the number of episodes prevented for outcome variables (number of asthma attacks, urgent medical examinations, admission days, and working days lost). Direct costs Costs were not discounted because of the one-year follow-up of the study. Quantities (specifically time consumption) were reported separately (...) Economic analysis of two structured treatment and teaching programs on asthma Economic analysis of two structured treatment and teaching programs on asthma Economic analysis of two structured treatment and teaching programs on asthma Neri M, Migliori G B, Spanevello A, Berra D, Nicolin E, Landoni C V, Ballardini L, Sommaruga M, Zanon P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary

1996 NHS Economic Evaluation Database.

1092. An intervention program to reduce the hospitalization cost of asthmatic patients requiring intubation

with potentially fatal asthma Source of funding Supported by UPHS Grant AI 11403 and the Ernest S Bazley Grant to Northwestern memorial Hospital and Northwestern University. Bibliographic details Doan T, Grammer L C, Yarnold P R, Greenberger P A, Patterson R. An intervention program to reduce the hospitalization cost of asthmatic patients requiring intubation. Annals of Allergy, Asthma and Immunology 1996; 76(6): 513-518 Other publications of related interest Detjen PF, Greenberger PA, Grammer LC, Patterson R (...) An intervention program to reduce the hospitalization cost of asthmatic patients requiring intubation An intervention program to reduce the hospitalization cost of asthmatic patients requiring intubation An intervention program to reduce the hospitalization cost of asthmatic patients requiring intubation Doan T, Grammer L C, Yarnold P R, Greenberger P A, Patterson R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each

1996 NHS Economic Evaluation Database.

1093. Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden

Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden Gerdtham U G, Hertzman P, Jonsson B, Boman G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Inhaled corticosteroids in the treatment of asthmatic patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Swedish inhabitants. Setting Clinic. The economic study was carried out in Sweden. Dates to which data relate The effectiveness and resource utilisation data were collected between 1978 and 1991 (except for 1984 in-patient care data which were

1996 NHS Economic Evaluation Database.

1094. A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma

in a longer observation period (longer than 8 weeks). Source of funding Supported by Glaxo Wellcome resources. Bibliographic details Booth P C, Wells N E, Morrison A K. A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma. PharmacoEconomics 1996; 10(3): 262-268 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Administration, Inhalation; Androstadienes /administration & Anti-Asthmatic Agents /administration & Asthma /economics /physiopathology (...) A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma Booth P C, Wells N E, Morrison A K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods

1996 NHS Economic Evaluation Database.

1095. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice

the perspective of a third party payer and it might have been interesting to determine whether there were any costs to other groups in society such as patients themselves due to differences in the incidence of asthmatic symptoms. Other issues The results of the economic analysis may not be generalisable outside the specific patient population and treatment protocols may also vary elsewhere compared with those in Canada. Only adult patients were included in the analysis, yet asthma affects many children (...) 1996; 3(3): 169-175 Original Paper URL Other publications of related interest Evans M F and Frank J. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. Canadian Family Physician 1997;43:632-633. Indexing Status Subject indexing assigned by NLM MeSH Administration, Inhalation; Adult; Anti-Asthmatic Agents /therapeutic use; Anti-Inflammatory Agents /therapeutic use /economics; Asthma /drug therapy; Bronchodilator Agents

1996 NHS Economic Evaluation Database.

1096. Zafirlukast (Accolate) in asthma

use as Step 2 treatment, but results of direct comparative trials with corticosteroids are awaited. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Adrenal Cortex Hormones; Anti-Asthmatic Agents /therapeutic use; Asthma /drug therapy; Costs and Cost Analysis; Receptors, Leukotriene /antagonists & inhibitors Language Published English Country of organisation England Address for correspondence Pauline King. Wessex Institute for Health Research and Development, Boldrewood (...) Zafirlukast (Accolate) in asthma Zafirlukast (Accolate) in asthma Zafirlukast (Accolate) in asthma Booth-Clibborn N, Best L, Stevens A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Booth-Clibborn N, Best L, Stevens A. Zafirlukast (Accolate) in asthma. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1996 Authors

1996 Health Technology Assessment (HTA) Database.

1097. Effect of domestic concentrations of nitrogen dioxide on airway responses to inhaled allergen in asthmatic patients. (Abstract)

Effect of domestic concentrations of nitrogen dioxide on airway responses to inhaled allergen in asthmatic patients. Nitrogen dioxide is a common indoor pollutant. In the light of suggestions that outdoor air pollution can harm people with asthma, we investigated the effect of 1 h exposures to domestic concentrations of nitrogen dioxide on the airway response to house-dust mite (HDM) allergen in ten patients with mild asthma. Each subject breathed air, 100 ppb nitrogen dioxide, or 400 ppb (...) nitrogen dioxide for 1 h, in double-blind, random order, then immediately underwent a fixed-dose HDM challenge. Baseline forced expiratory volume in 1 s (FEV1) was not affected by any of the gas mixtures. The mean early asthmatic response (maximum percentage change in FEV1 during first 2 h after challenge) was -14.62% (SD 8.03) after air, -14.41% (7.86) after 100 ppb nitrogen dioxide, and -18.64% (7.28) after 400 ppb nitrogen dioxide. The difference between air and 400 ppb (-4.01%) was significant (95

1995 Lancet Controlled trial quality: uncertain

1098. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. (Abstract)

Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. In view of current concerns about use of regular beta-2 agonists, and the place of the newer long-acting drugs, we decided to evaluate whether continuous exposure to twice daily salmeterol results in a blunting of the acute bronchodilator response to repeated doses of salbutamol, as might be administered in the management of an acute asthma attack. After a 2 week run-in without beta-2 agonists, 17 (...) asthmatic patients (mean [SE] age 34 [3] years, mean forced expiratory volume in 1 s [FEV1] 64 [2.7]% of predicted) were randomised to receive salmeterol 50 micrograms twice daily or placebo for 4 weeks in a double-blind cross-over fashion. A histamine challenge test was done 12 h after the last dose of each treatment period, and dose-response curves to inhaled salbutamol (200-3200 micrograms) were constructed 36 h after the last dose. Patients treated with salmeterol had reduced bronchodilator

1995 Lancet Controlled trial quality: uncertain

1099. Using information from asthma patients: a trial of information feedback in primary care. Full Text available with Trip Pro

general practices, each of which notified at least 20 asthmatic patients aged 15-60 years for each principal. Practices were randomly allocated to an invention group (receiving feedback of information on control of asthma) or a control group (no feedback).Information on cards inserted in patients' medical records; booklet copies of information for team members; formal presentation to primary care teams; poster displays of data on patients in each practice.Type and frequency of asthma symptoms, use (...) Using information from asthma patients: a trial of information feedback in primary care. To test the effects of feedback of information about patients' asthma to primary care teams.Patients' reports of morbidity, use of health services, and drug use on questionnaire was given to primary care teams. Randomised controlled trial with general practices as the subject of the intervention was used to test effectiveness of supplying information.Primary care in district health authority, London.23

1995 BMJ Controlled trial quality: uncertain

1100. Controlled trial of an audit facilitator in diagnosis and treatment of childhood asthma in general practice. Full Text available with Trip Pro

Controlled trial of an audit facilitator in diagnosis and treatment of childhood asthma in general practice. To test whether an audit facilitator could alter the pattern of diagnosis and treatment of childhood asthma.Randomised stratified controlled trial.12 general practices in Tayside.3373 children aged 1-15 inclusive who had symptoms suggestive of asthma or possible asthma drawn from a systematic review of 10,725 general practice case records.Children were targeted for a clinical review (...) by their general practitioner or practice nurses.Asthma related consultations, prescriptions, hospital attendances, and health service costs 12 months before and after study.Compared with controls (n = 1563) the intervention group (n = 1585) had more practice initiated consultations for asthma (relative risk 2.18 (95% confidence interval 1.74 to 2.73)), new diagnoses of asthma (2.83 (2.26 to 3.54)), and past diagnoses reaffirmed (1.30 (1.08 to 1.58)), and they were more frequently prescribed inhaled

1995 BMJ Controlled trial quality: predicted high